Drug intelligence / Profile preview

Maalox Plus

Development stage: Unknown
Lead developer: Sanofi
Modality: Small Molecules
Administration: Oral

Overview

Maalox Plus is an over-the-counter combination medication used to treat symptoms of excess stomach acid and intestinal gas. It contains two antacids, aluminium hydroxide and magnesium hydroxide, which work by neutralizing gastric acid to relieve heartburn and indigestion. The third component, simeticone, is an antifoaming agent that reduces the surface tension of gas bubbles in the digestive tract, allowing them to be expelled more easily. Developed by Opella Healthcare (a Sanofi subsidiary), it is typically administered as an oral suspension for the relief of dyspepsia, bloating, and flatulence.

Brand names: Maalox Plus
Other names: aluminium hydroxide + magnesium hydroxide + simeticone

Beyond the preview

Go deeper on Maalox Plus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maalox Plus.

Explore the full profile